- Schering-Plough Tries to Deal Its Way to Top
- Mar 13 | The Wall Street Journal | After spending the past four years patiently nursing midsize drug maker Schering-Plough Corp. back to health, veteran pharmaceutical-industry executive Fred Hassan resumed doing what he loves most: making deals. more
- Schering-Plough to Buy Akzo's Drug-Making Division for $14.4B
- Mar 12 | Bloomberg.com | Schering-Plough Corp. agreed to buy Akzo Nobel NV's drug-making division Organon for $14.4 billion in cash to gain the world's third-largest maker of birth-control pills and a stable of experimental medicines. more
- Novartis Rally Seen on Key U.S. Drug Approval
- Mar 06 | Reuters | Swiss drug group Novartis has received its first U.S. approval for the potential blockbuster blood pressure drug Tekturna, in a move expected to spark a rally in Novartis shares. more
- A Rock Star of Biotechs Plans IPO
- Mar 06 | The Boston Globe | Sirtris Pharmaceuticals Inc. , a young Cambridge, Mass., biotechnology company trying to parlay life-extension research into drugs for diabetes and other metabolic problems, hopes to raise up to $60 million in an initial public offering. more
- Glaxo Pipeline Dented as Mid-Stage Drugs Dropped
- Mar 05 | Reuters | GlaxoSmithKline Plc's claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing. more
- Gene Logic Says May Spin Off Genomics Division
- Feb 26 | Reuters | Gene Logic Inc. on Friday said it may spin off its genomics business, while continuing to retain a stake in the struggling segment. more
- FDA Delays Approval of Novartis Diabetes Drug
- Feb 26 | The Wall Street Journal | Novartis AG said Monday that the FDA requested it to conduct an additional study on experimental diabetes drug Galvus before approving it, delaying by about a year the launch of one of the company's most important new products. more
Feeds